Leonard Post

Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia.

Altiris Therapeutics, Inc. develops and commercializes small-molecule drug therapies. The company was founded by Dennis Liotta, Hyunsuk Shim and James P. Snyder in 2005 and is headquartered in Atlanta, GA.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.

BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK.

Orphagen Pharmaceuticals develops and manufactures drugs. The company was founded by Scott Thacher in 2001 and is headquartered in San Diego, CA.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Virtuoso Therapeutics, Inc. is an oncology-focused small molecule drug discovery and development company. The company is headquartered in San Mateo, CA.

ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019.

AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018.